Company registration number 09794537 (England and Wales)
Farmigea Ophthalmics Limited
Audited Financial Statements
For the year ended
31 December 2024
Pages for filing with registrar
Farmigea Ophthalmics Limited
Contents
Page
Statement of financial position
1
Notes to the financial statements
2 - 6
Farmigea Ophthalmics Limited
Statement Of Financial Position
As at 31 December 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
4
1,704
-
0
Current assets
Stocks
536,576
315,238
Debtors
5
733,325
469,275
Cash at bank and in hand
18,844
20,518
1,288,745
805,031
Creditors: amounts falling due within one year
6
(1,196,705)
(780,644)
Net current assets
92,040
24,387
Net assets
93,744
24,387
Capital and reserves
Called up share capital
10,000
11,500
Share premium account
366,300
366,300
Profit and loss reserves
(282,556)
(353,413)
Total equity
93,744
24,387

The notes on pages 2 to 6 form part of these financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the income statement within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 24 December 2025 and are signed on its behalf by:
A. John
Director
Company registration number 09794537 (England and Wales)
Farmigea Ophthalmics Limited
Notes To The Financial Statements
For the year ended 31 December 2024
- 2 -
1
General information

Farmigea Ophthalmics Limited is a private company limited by shares incorporated in England and Wales. The registered office is Dixcart House, Addlestone Road, Bourne Business Park, Addlestone, Surrey, KT15 2LE.

2
Accounting policies
2.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, The principal accounting policies adopted are set out below.

2.2
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future.

 

The company has been profit making in the last four financial years and the directors expect the company to remain profit making for the foreseeable future. The directors also expect the continued financial support of the shareholders, who have confirmed their intention to support the company for all third party liabilities arising for a period of at least twelve months from the date of signing of the financial statements. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

2.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Farmigea Ophthalmics Limited
Notes To The Financial Statements (Continued)
For the year ended 31 December 2024
2
Accounting policies
(Continued)
- 3 -
2.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
20% straight line
Equipment
33% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

2.5
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

2.6
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

2.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand.

2.8
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors, are initially recognised at transaction price. Financial liabilities classified as payable within one year are not amortised.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less.

Farmigea Ophthalmics Limited
Notes To The Financial Statements (Continued)
For the year ended 31 December 2024
2
Accounting policies
(Continued)
- 4 -
2.9
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

2.10
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense.

2.11
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2.12
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
1
1
Farmigea Ophthalmics Limited
Notes To The Financial Statements (Continued)
For the year ended 31 December 2024
- 5 -
4
Tangible fixed assets
Fixtures and fittings
Equipment
Total
£
£
£
Cost
At 1 January 2024
625
3,557
4,182
Additions
-
0
1,858
1,858
At 31 December 2024
625
5,415
6,040
Depreciation and impairment
At 1 January 2024
625
3,557
4,182
Depreciation charged in the year
-
0
154
154
At 31 December 2024
625
3,711
4,336
Carrying amount
At 31 December 2024
-
0
1,704
1,704
At 31 December 2023
-
0
-
0
-
0
5
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
599,655
456,039
Other debtors
133,670
8,926
733,325
464,965
2024
2023
Amounts falling due after more than one year:
£
£
Deferred tax asset
-
0
4,310
Total debtors
733,325
469,275
6
Creditors: amounts falling due within one year
2024
2023
£
£
Trade creditors
927,307
540,362
Corporation tax
15,170
-
0
Other taxation and social security
71,348
94,682
Other creditors
182,880
145,600
1,196,705
780,644
Farmigea Ophthalmics Limited
Notes To The Financial Statements (Continued)
For the year ended 31 December 2024
- 6 -
7
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.

The auditor's report is unqualified and includes the following:

Opinion

In our opinion the financial statements:

Senior Statutory Auditor:
Julia Wigram FCA
Statutory Auditor:
Dixcart Audit LLP
Date of audit report:
24 December 2025
8
Capital commitments

Amounts contracted for but not provided in the financial statements:

2024
2023
£
£
Acquisition of intangible assets
82,722
-
9
Related party transactions

At the balance sheet date, the company was owed a total of £3,800 (2023: £5,300) from shareholders holding participating interests, in respect of unpaid share capital. This amount is shown within other debtors, is unsecured, interest free and repayable on demand.

10
Directors' transactions

At the balance sheet date a director owed the company £120 (2023: £nil). This amount is shown within other debtors and is unsecured, interest free and repayable on demand.

2024-12-312024-01-01falsefalsefalse24 December 2025CCH SoftwareCCH Accounts Production 2025.300No description of principal activityA. JohnG. Zalum097945372024-01-012024-12-31097945372024-12-31097945372023-12-3109794537core:FurnitureFittings2024-12-3109794537core:ComputerEquipment2024-12-3109794537core:FurnitureFittings2023-12-3109794537core:ComputerEquipment2023-12-3109794537core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3109794537core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-3109794537core:CurrentFinancialInstruments2024-12-3109794537core:CurrentFinancialInstruments2023-12-3109794537core:ShareCapital2024-12-3109794537core:ShareCapital2023-12-3109794537core:SharePremium2024-12-3109794537core:SharePremium2023-12-3109794537core:RetainedEarningsAccumulatedLosses2024-12-3109794537core:RetainedEarningsAccumulatedLosses2023-12-3109794537bus:Director12024-01-012024-12-3109794537core:FurnitureFittings2024-01-012024-12-3109794537core:ComputerEquipment2024-01-012024-12-31097945372023-01-012023-12-3109794537core:FurnitureFittings2023-12-3109794537core:ComputerEquipment2023-12-31097945372023-12-3109794537core:AfterOneYear2024-12-3109794537core:AfterOneYear2023-12-3109794537bus:PrivateLimitedCompanyLtd2024-01-012024-12-3109794537bus:SmallCompaniesRegimeForAccounts2024-01-012024-12-3109794537bus:FRS1022024-01-012024-12-3109794537bus:Audited2024-01-012024-12-3109794537bus:Director22024-01-012024-12-3109794537bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP